NL-OMON42033撤回4 期
A new dosing strategy of infliximab versus standard dosing in patients with severe sarcoidosis: optimization of treatment - Concentration guided dosing of infliximab in sarcoidosis
适应症
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •patients diagnosed with sarcoidosis being treated with infliximab or with an indication for infliximab;capability of giving informed consent
排除标准
- •vaccination with live viral or bacterial vaccines within the previous 3 months, or with the last dose within the previous 3 months;active or untreated latent tuberculosis (by mantoux-Elispot/TBC-IGRA);serious infections within the last 2 months;serious right ventricular heart failure or cor polmunale;Active hepatitis B;history of allergic reactions to monocolonal antibodies or their fragments;oppotunistic infections with the last 6 months;HIV;transplantation;known malignancy;pregnancy or breastfeeding
研究者
相似试验
进行中（未招募）
不适用
Infliximab dosing based on blood concentrations in patients with sarcoidosis: smart dosingSarcoidosisEUCTR2014-002224-26-NLSt. Antonius Hospital
进行中（未招募）
不适用
A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis. - DOSEModerate to severe plaque PsoriasisMedDRA version: 11.0Level: LLTClassification code 10037153Term: <Manually entered code. Term in E.1.1>EUCTR2008-000454-12-GRSchering Plough Research Institute, a Division of Schering Corporation200
进行中（未招募）
1 期
A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis. - DOSEModerate to severe plaque PsoriasisMedDRA version: 11.0Level: LLTClassification code 10037153Term: <Manually entered code. Term in E.1.1>EUCTR2008-000454-12-HUSchering Plough Research Institute, a Division of Schering Corporation200
进行中（未招募）
不适用
A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis. - DOSEEUCTR2008-000454-12-DESchering Plough Research Institute, a Division of Schering Corporation200
进行中（未招募）
不适用
A Study of Dose Optimization of Infliximab in the Treatment of Moderate to Severe Plaque Psoriasis. - DOSEEUCTR2008-000454-12-GBSchering Plough Research Institute, a Division of Schering Corporation200